Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thebaine SCHEMBL13154680 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL18457566 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL12137749 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL37580 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL12646311 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL173212 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL17284777 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL3122741 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL12960959 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 | |
| Thebaine SCHEMBL21131556 | 1.00 | OPRM1 (1.00) | OPRM1MRGPRX2L3MBTL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321269-B1 | PROCESS FOR PREPARING BUPRENORPHINE INTERMEDIATES | JOHNSON MATTHEY PLC (GB) | 2020-04-29 | — | — | EP | disclosed |
| US-10208054-B2 | Method of preparing buprenorphine | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-02-19 | — | — | US | disclosed |
| EP-2763996-B1 | PROCESS FOR PREPARING BUPRENORPHINE | JOHNSON MATTHEY PLC (GB) | 2018-07-25 | — | — | EP | disclosed |
| EP-3321269-A1 | PROCESS FOR PREPARING BUPRENORPHINE INTERMEDIATES | Johnson Matthey Public Limited Company (GB) | 2018-05-16 | — | — | EP | disclosed |
| US-20170217978-A1 | METHOD OF PREPARING BUPRENORPHINE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-08-03 | — | — | US | disclosed |
| US-20170217978-A1 | METHOD OF PREPARING BUPRENORPHINE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-08-03 | — | — | US | disclosed |
| US-9624231-B2 | Method of preparing buprenorphine | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9624231-B2 | Method of preparing buprenorphine | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-04-18 | — | — | US | disclosed |
| EP-2480555-B1 | METHODS FOR PRODUCING HYDROCODONE, HYDROMORPHONE OR A DERIVATIVE THEREOF | MALLINCKRODT LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8853401-B2 | Processes for the preparation of morphinane and morphinone compounds | BROCK UNIVERSITY (CA) | 2014-10-07 | — | — | US | disclosed |
| US-20110071297-A1 | Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof | MALLINCKRODT INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100087647-A1 | Processes for the production of buprenorphine with reduced impurity formation | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087647-A1 | Processes for the production of buprenorphine with reduced impurity formation | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010039220-A1 | PROCESSES FOR THE PRODUCTION OF BUPRENORPHINE WITH REDUCED IMPURITY FORMATION | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100048905-A1 | Novel Opiate Reduction Utilizing Catalytic Hydrogen Transfer Reaction | STRATATECH CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20100048905-A1 | Novel Opiate Reduction Utilizing Catalytic Hydrogen Transfer Reaction | STRATATECH CORPORATION | 2010-02-25 | — | — | US | disclosed |
| EP-1981891-B1 | THE USE OF ORIPAVINE AS A STARTING MATERIAL FOR BUPRENORPHINE | MALLINCKRODT INC (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008130553-A1 | NOVEL OPIATE REDUCTION UTILIZING CATALYTIC HYDROGEN TRANSFER REACTION | MALLINCKRODT INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080207906-A1 | Synthetic Route to 14-Hydroxyl Opiates Through 1-Halo-Thebaine or Analogs | MALLINCKRODT ENTERPRISES LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207906-A1 | Synthetic Route to 14-Hydroxyl Opiates Through 1-Halo-Thebaine or Analogs | MALLINCKRODT ENTERPRISES LLC | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048905-A1 | Novel Opiate Reduction Utilizing Catalytic Hydrogen Transfer Reaction | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885MRGPRX2 3333/4885L3MBTL1 4475/4885 |
| US-20080207906-A1 | Synthetic Route to 14-Hydroxyl Opiates Through 1-Halo-Thebaine or Analogs | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885MRGPRX2 1172/4885L3MBTL1 1257/4885 |
| US-20170217978-A1 | METHOD OF PREPARING BUPRENORPHINE | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885MRGPRX2 1972/4885L3MBTL1 2641/4885 |
| US-20100087647-A1 | Processes for the production of buprenorphine with reduced impurity formation | CYP3A5, OPRM1, OPRK1 | OPRM1 2/4885MRGPRX2 2569/4885L3MBTL1 945/4885 |
| US-20110071297-A1 | Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof | OPRK1, OPRD1, HAAO | OPRM1 4/4885MRGPRX2 2968/4885L3MBTL1 2771/4885 |
| US-10208054-B2 | Method of preparing buprenorphine | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885MRGPRX2 1972/4885L3MBTL1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.